Cardiac Pharmacology: Difference between revisions

no edit summary
No edit summary
 
Line 621: Line 621:
|-
|-
|rowspan="3"|PCSK9 Inhibitors
|rowspan="3"|PCSK9 Inhibitors
|Evolocumab, Alirocumab, Bococizumab, Inclisiran
|Evolocumab, Alirocumab, Inclisiran
|Primary hypercholesterolemia, Mixed Dyslipidemia, Homozygous Familial Hypercholesterolemia
|Primary hypercholesterolemia, Mixed Dyslipidemia, Homozygous Familial Hypercholesterolemia
|Evolocumab: 140mg every 2 weeks or 420mg once monthly
|Evolocumab: 140mg every 2 weeks or 420mg once monthly
Alirocumab: 75mg to 150mg every 2 weeks
Alirocumab: 75mg to 150mg every 2 weeks
Bococizumab and Inclisiran dosages according to specific treatment regimes
Inclisiran dosages according to specific treatment regimes
|Primary hypercholesterolemia and Mixed Dyslipidemia: Class I; Homozygous Familial Hypercholesterolemia: Class I <cite>Esc2</cite> <cite>Esc3</cite>
|Primary hypercholesterolemia and Mixed Dyslipidemia: Class I; Homozygous Familial Hypercholesterolemia: Class I <cite>Esc2</cite> <cite>Esc3</cite>
|Injection site reactions (5.9%), nasopharyngitis (5.5%), upper respiratory tract infections (2.3%), flu (3.1%), back pain (3.2%), hypersensitivity reactions including rash, pruritus (1.7%), and rare cases of neurocognitive effects such as memory loss or confusion.
|Injection site reactions (5.9%), nasopharyngitis (5.5%), upper respiratory tract infections (2.3%), flu (3.1%), back pain (3.2%), hypersensitivity reactions including rash, pruritus (1.7%), and rare cases of neurocognitive effects such as memory loss or confusion.